Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Naber

Showing results (181-190 of 195) with videos related to

Pageof 20
Sort By:
European Psychiatry : the Journal of the Association of European Psychiatrists|June 30, 2009
Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic studyM Jäger, M Schmauss, G Laux, et al.
Pharmacopsychiatry|September 3, 2008
Standardized remission criteria in schizophrenia: descriptive validity and comparability with previously used outcome measuresM Jäger, T Messer, G Laux, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|May 1, 2012
Insight in schizophrenia-course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorderR Schennach, S Meyer, F Seemüller, et al.
Fortschritte Der Neurologie-Psychiatrie|November 7, 2013
[Mental health of children, adolescents and young adults--part 1: prevalence, illness persistence, adversities, service use, treatment delay and consequences]M Lambert, T Bock, D Naber, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|December 27, 2014
What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?R Schennach, M Riedel, M Obermeier, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 8, 2010
Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidoneM A Crocq, D Naber, M H Lader, et al.
Fortschritte Der Neurologie-Psychiatrie|November 7, 2013
[Mental health of children, adolescents and young adults--part 2: burden of illness, deficits of the German health care system and efficacy and effectiveness of early intervention services]A Karow, T Bock, D Naber, et al.
Acta Psychiatrica Scandinavica|October 30, 2010
Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression ScaleR Schennach-Wolff, M Obermeier, F Seemüller, et al.
Acta Psychiatrica Scandinavica|April 14, 2010
Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP)S H L Thomas, M D Drici, G C Hall, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|May 4, 2010
Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disordersR Schennach-Wolff, F Seemüller, M Obermeier, et al.
Pageof 20

Showing results (181-190 of 195) with videos related to

Sort By:
Pageof 20
European Psychiatry : the Journal of the Association of European Psychiatrists|June 30, 2009
Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic studyM Jäger, M Schmauss, G Laux, et al.
Pharmacopsychiatry|September 3, 2008
Standardized remission criteria in schizophrenia: descriptive validity and comparability with previously used outcome measuresM Jäger, T Messer, G Laux, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|May 1, 2012
Insight in schizophrenia-course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorderR Schennach, S Meyer, F Seemüller, et al.
Fortschritte Der Neurologie-Psychiatrie|November 7, 2013
[Mental health of children, adolescents and young adults--part 1: prevalence, illness persistence, adversities, service use, treatment delay and consequences]M Lambert, T Bock, D Naber, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|December 27, 2014
What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?R Schennach, M Riedel, M Obermeier, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 8, 2010
Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidoneM A Crocq, D Naber, M H Lader, et al.
Fortschritte Der Neurologie-Psychiatrie|November 7, 2013
[Mental health of children, adolescents and young adults--part 2: burden of illness, deficits of the German health care system and efficacy and effectiveness of early intervention services]A Karow, T Bock, D Naber, et al.
Acta Psychiatrica Scandinavica|October 30, 2010
Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression ScaleR Schennach-Wolff, M Obermeier, F Seemüller, et al.
Acta Psychiatrica Scandinavica|April 14, 2010
Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP)S H L Thomas, M D Drici, G C Hall, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|May 4, 2010
Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disordersR Schennach-Wolff, F Seemüller, M Obermeier, et al.
Pageof 20